The latest trading session saw Pfizer (PFE) ending at $24.70, denoting a +0.65% adjustment from its last day's close. This change lagged the S&P 500's 0.67% gain on the day. Meanwhile, the Dow experienced a rise of 0.56%, and the technology-dominated Nasdaq saw an increase of 0.87%.
Heading into today, shares of the drugmaker had lost 4.7% over the past month, outpacing the Medical sector's loss of 5.32% and the S&P 500's loss of 5.28% in that time.
Analysts and investors alike will be keeping a close eye on the performance of Pfizer in its upcoming earnings disclosure. The company's earnings report is set to go public on April 29, 2025. The company's upcoming EPS is projected at $0.68, signifying a 17.07% drop compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $13.99 billion, down 5.97% from the year-ago period.
PFE's full-year Zacks Consensus Estimates are calling for earnings of $2.97 per share and revenue of $63.2 billion. These results would represent year-over-year changes of -4.5% and -0.67%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Pfizer. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.42% higher within the past month. Currently, Pfizer is carrying a Zacks Rank of #3 (Hold).
In terms of valuation, Pfizer is presently being traded at a Forward P/E ratio of 8.26. This denotes a discount relative to the industry's average Forward P/E of 13.71.
It's also important to note that PFE currently trades at a PEG ratio of 0.6. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.31 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 67, which puts it in the top 27% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow PFE in the coming trading sessions, be sure to utilize Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
